Medicine

Earlier Interferon Reduces Disability in Patients With Multiple Sclerosis

Ludwig Kappos
Ludwig Kappos

REFERENCE: Lancet 2007; 370: 389-97
LUDWIG KAPPOS, University Hospital, Basel
Earlier treatment can reduce the risk of confirmed disability in patients with multiple sclerosis, according to a new study published in the Lancet. Three-year follow-up of the BENEFIT study showed favourable results among patients who began treatment with interferon beta-1b after a first event suggestive of multiple sclerosis, rather than waiting for further confirmatory events. Nicola Solomon interviewed Ludwig Kappos.

Similar Interviews

  • Natalizumab Risks and Benefits in Multiple Sclerosis
  • Chris Polman, Free University of Amsterdam Abstract N Engl J Med 2006;345:899 Despite fears that natalizumab - which reduces progression in some

  • Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability
  • Peter Tyrer REFERENCE: Lancet 371:57 January 5, 2008 PETER TYRER, Imperial College, W6 8RP

  • Targeted Therapies in Multiple Myeloma Treatment Decisions
  • Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma

    Post a comment

    Subscribe to Audio Medica Podcast